BeiGene is advancing a hematologic malignancy pipeline consisting of novel oral small molecules and monoclonal antibodies. Among these are zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor and BGB-11417, a BCL2 inhibitor, both for the treatment of various B-cell malignancies.
Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).
Slide kit describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
